This offer is aimed at Swedish parties seeking funding in the international call JPI AMR 2022 (Joint Programming Initiative Antimicrobial Resistence 2022) with a focus on innovative drug design. All information about the specialization, how to apply and what is funded can be found on the international call website.
JPI AMR is responsible for the application function and the assessment of proposal. Vinnova's role is to finance the Swedish parties in the project that are assessed positively by JPI AMR and meet Vinnova's national eligibility requirements for funding. For this reason, the projects seeking funding from JPI AMR will also submit a proposal to Vinnova. If two Swedish parties participate in an international consortium, they must submit a joint proposal. Vinnova participates in this call for proposals together with the Swedish Research Council and SIDA. Swedish project partners in a consortium seeking funding from Vinnova must consist of at least one participant from industry (small or medium-sized companies and large companies). Swedish applicant without industrial participation are referred to the Swedish Research Council.
Swedish parties from academia, institutes, idea-driven organizations and the public sector and care providers can apply for 100% cost coverage if the activities are included in their non-financial activities. Large companies can apply for 20% of the eligible costs, small and medium-sized enterprises can apply for up to 70% of the eligible costs.
Vinnova finances a Swedish industrial party in a consortium with a maximum of SEK 3 million over three years. If more Swedish parties are included, the total financing can amount to a maximum of SEK 4.5 million. However, no party can apply for more than SEK 3 million.
Participant applying for funding must be a Swedish legal entity (organization) in Sweden. In this respect, a Swedish legal entity (organization) is equated with a foreign organization that has a branch or place of business in Sweden (the costs of the project must be attributable to the branch's or place of business's activities).
This call for proposals is the 14th call within the framework of The Joint Programming Initiative on Antimicrobial Resistance, JPI AMR. The call is coordinated by ERA-Net JPIAMR-ACTION and brings together 26 organizations from 17 countries to invest in transnational collaborative research and innovation.
This call for proposals (Disrupting drug resistance using innovative design) aims to improve the treatment of bacterial and fungal infections (including co-infection) and / or prevent the emergence / spread of resistance in humans, animals or plants by improving efficiency, specificity, delivery, the combinations and / or reuse of medicinal products and plant protection products. For a complete description, see the international call website.
Project proposals should focus on licensed antimicrobials (antibiotics / antifungals) or agents in preclinical and / or early clinical development, and should address at least one of the following substances.
- Improving the effectiveness and / or specificity of the medicinal product / plant protection product through chemical modifications (including hit-to-lead optimization).
- New uses for existing medicinal / plant protection products.
- Optimization of combinations of drugs / plant protection products, single or with additional treatments (including therapeutic vaccines).
- Design and implementation of new strategies (including optimization of drug dosage) for improved application, efficacy and delivery of individual or combinations of antimicrobials.
- Design and develop innovative tools, including new chemistry and / or new materials for improved application, effect and delivery of antimicrobial methods.
Each consortium must consist of at least three different organizations (eligible for funding) from three different countries. A maximum of two organizations from each country may be part of a consortium.
To apply for funding from Vinnova, it is important to follow the formal requirements under heading 7.